Researchers and physicians specializing in treating patients with radiation therapy at the UCLA Health Johnson Comprehensive Cancer Center will be speaking at the 66th American Society of Radiation Oncology (ASTRO) Annual Meeting on September 29 in Washington, DC. , will present data on the latest radiation oncology research and clinical trial results. Until October 2nd.
The premier conference in radiation oncology, this annual conference covers survival rates, lung cancer/thoracic malignancies, physics, sarcomas, gastrointestinal cancers, genitourinary cancers, gynecological cancers, pediatric cancers, and diversity in medicine. gender, equity, and inclusion.
“Our team is proud to present research that pushes the boundaries of what is possible in radiation oncology,” said David Geffen, professor of medicine and professor of radiation oncology at UCLA, and professor of radiation oncology at UCLA Health. said Dr. Michael Steinberg, the bureau’s clinical director. Johnson Comprehensive Cancer Center. “From innovative approaches in chemoradiotherapy and symptom monitoring to advances in MRI-guided radiotherapy, these studies demonstrate our commitment to improving patient outcomes and shaping the future of cancer treatment. is emphasized.”
Highlights of notable presentations at ASTRO led by UCLA researchers include:
Abstract 1071: MicroRNA-based germline biomarkers of pathological complete response to neoadjuvant chemoradiotherapy in rectal cancer
The research team, led by Dr. Joan Wideharth, professor of radiation oncology, associate professor of molecular and cellular oncology, and director of translational research at the David Geffen School of Medicine at the University of California, Los Angeles, is investigating which patients are locally infected. We identified a genetic signature that can help make predictions. Advanced rectal cancer is most likely to achieve a complete pathological response after treatment with combined chemotherapy and radiotherapy. Prior to this study, no molecular-based assays existed to predict which patients are most likely to benefit from chemoradiotherapy and inform treatment selection. The study, conducted in 90 rectal cancer patients, identified microRNA-associated single nucleotide polymorphisms (microRNA-associated single nucleotide polymorphisms), genetic variations that can disrupt microRNA signaling, a key process that regulates gene expression. miSNP). By analyzing mirSNPs in combination with clinical variables such as age, tumor stage, and KRAS mutation status, researchers have demonstrated the powerful ability to identify patients who achieve complete remission with no viable tumor cells remaining after treatment. We developed a predictive model with Predictive models built using advanced statistical techniques performed better than models based solely on clinical factors. This model provides a more personalized approach that can identify patients most likely to respond to this therapeutic approach, potentially helping to avoid unnecessary surgery. The research team plans to validate these findings in a larger patient cohort and further investigate the ability of the mirSNP signature to predict treatment toxicity.
Wideharth will present his findings in the session “QP 13-GI 4: GI Cancers: From Top to Bottom” on Tuesday, October 1 at 4:00 pm ET in Room 152.
Abstract 317: Magnetic resonance imaging-guided versus computed tomography-guided stereotactic radiotherapy for prostate cancer: 2-year results of the MIRAGE randomized clinical trial
In a secondary analysis of a randomized phase 3 clinical trial comparing two methods of guiding stereotactic radiation therapy (SBRT) for prostate cancer, researchers found that patients treated with MRI guidance experienced fewer long-term side effects. They found that the quality of life related to bowel and sexual activity was improved. Health status compared to patients treated with CT guidance. Prostate cancer is one of the most common cancers among men, and radiation therapy is a standard treatment option, especially for those with localized disease. However, the side effects of treatment can be severe and long-lasting, affecting the patient’s urinary, intestinal, and sexual function. The team, led by Dr. Amar Kishan, vice chair of radiation oncology at the David Geffen School of Medicine at the University of California, Los Angeles, found that patients treated with MRI-guided SBRT had lower grade 2 or higher genitourinary and gastrointestinal It was discovered that the toxic effects on CT-guided treatment. Specifically, only 27% of MRI-guided patients reported late genitourinary toxicity, such as urinary incontinence or irritation, compared to 51% of the CT-guided group. Similarly, gastrointestinal toxicities, such as intestinal problems, were reduced from 9% with CT guidance to just 1.4% with MRI guidance. The study followed patients for two years after treatment, making it one of the most comprehensive evaluations of MRI-guided SBRT to date.
Dr. Kishan will present his research findings in the session “SS 38-GU 2: Optimizing Prostate Cancer Treatment Rates” on Tuesday, October 1 at 2:30 PM ET in Room 202. Masu.
Summary 122: Symptom monitoring with patient-reported outcomes during definitive radiotherapy
In this Phase 2 study, led by Dr. Anne Lardeau, associate professor of radiation oncology at the David Geffen School of Medicine at the University of California, Los Angeles, researchers tested patients who reported symptoms using a mobile app called mPROS. , evaluated whether the quality of life of patients with the following symptoms improved: Cancer receiving radiation therapy. Although the use of patient-reported outcomes has shown benefits in improving clinical outcomes for patients receiving chemotherapy, its effectiveness in the radiotherapy setting is not well established. This study aimed to fill that gap by comparing patients who reported symptoms using the mPROS app with those receiving usual care. The study included patients receiving radical radiotherapy alongside chemotherapy for a variety of cancers, including gastrointestinal, gynecological, lung, central nervous system, and head and neck cancers. Patients participated. Participants were randomly assigned to either an experimental group using the mPROS app or a control group. Patients in the experimental group were encouraged to report their symptoms at least weekly through the app, and clinical teams were automatically alerted if symptoms became severe or worsened. The researchers then measured the impact of this approach on health-related quality of life using a validated questionnaire at the beginning, end, and three months after radiation therapy ended. Results showed no significant differences in physical or mental health outcomes between the two groups. However, patients who use the mPROS app report higher levels of satisfaction, feel more engaged in their care, and find the app helpful in tracking their symptoms. The majority of participants in the experimental group said they would recommend the app to other patients.
Mr. Lardo will present his findings in Session: SS 04 – PRO/QoL/Survival 1: New Frontiers in Patient-Reported Outcomes and Survival on Sunday, September 19th at 3:45 PM EST in Room 204 I will.
sauce:
University of California, Los Angeles Health Sciences
